A bilateral treatment restore expression levels of PMP22 comparable to wild-type conditions, resulting in increased myelination and prevention of motor and sensory impairments over a twelve-months period in a rat model of CMT1A. The gene discussed is PMP22; the disease is Charcot-Marie-Tooth disease type 1A.